ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed 08 December 8:00AM
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
42.20
Bid
41.80
Offer
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
02opida 02opida 2 minutes ago
WASHINGTON—President-elect Donald Trump’s transition team is drafting several versions of his long-promised executive order to curtail automatic citizenship for anyone born in the U.S., according to people familiar with the matter, as his aides prepare for an expanded legal fight.

Tru
JOoa0ky JOoa0ky 4 minutes ago
Incorrect. $3.50 wall holds.
FNMA
02opida 02opida 4 minutes ago
Trump Prepares for Legal Fight Over His ‘Birthright Citizenship’ Curbs
02opida 02opida 6 minutes ago
OPEC+ extends its production cuts. MEG Energy wins a nod of approval from Fitch Ratings, while Kiwetinohk Energy has its eye on Alberta's data centre dreams. Kolibri Global cheers on its wells in Oklahoma, and LNG Energy puts itself up for sale
02opida 02opida 7 minutes ago
HII - HII Christens Virginia-Class Attack Submarine Arkansas (SSN 800)
HII
02opida 02opida 7 minutes ago
SNDX - Syndax Presents Positive Revuforj(TM) (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
SNDX
Humbert Humbert 7 minutes ago
Should skyrocket shortly
BNCM
02opida 02opida 7 minutes ago
ADPT - Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ(TM) and Its Impact on Blood Cancer Treatment Decisions
closetokathy closetokathy 9 minutes ago
What exactly is Kate trying to accomplish? Does anyone know? I wish her luck as I have my eyes set on a Toyota Prius.
CEOS
hnbadger1 hnbadger1 10 minutes ago
http://cslide.ctimeetingtech.com/a

SAVXL wow, now famous Prof Timo Grimmer,
¡Technical University Munich, involved in the study, is presenting in Vienna, April AD/PD:
PHASE IIB/III ATTENTION-AD STUDY: OVER THREE YEARS OF CONTINUOUS TREATMENT WITH ORAL BLARCAMESINE CONTIN
AVXL
Konaploinks Konaploinks 11 minutes ago
Ponderosa. Jensen has a few billion in pocket change to take IonQ anywhere it needs to go. He needs to diversify badly as the chip sharks are surrounding him. Ionq is the perfect fit and will bring in more rev to satisfy all shareholders. There would be no stopping him if he controlled quantum too.
IONQ
quester614 quester614 11 minutes ago
Not only a FLIPTARD but could be shorting this SCAM also. Is this the kind of frauds SP has warned us about. Making beer money while calling this a SCAM and attracts those who were long term holders. What a hypocritical FRAUD. Just an AGITATOR.

StockItOut
Re: FIREMEDIC0001 po
XERI
tedpeele tedpeele 11 minutes ago
Sad. The stock chart proves how wrong you are.

Ferrari man literally had a slide showing “commercialization polymer plus” in the middle of 2021. I listed 4 other examples disproving your take that he made it sound like it would take years. There’s no way the stock would have immediate
LWLG
capgain capgain 12 minutes ago
Amen!
MJAM2020 MJAM2020 12 minutes ago
Seamus Clause is coming tooo toowwn?

Imho
Mj
RNVA
CALLOUTTHETROLLS CALLOUTTHETROLLS 13 minutes ago
WAR.... This week your off the stock..... You are comical I give you that. Moves up you on it. Moves down you a Troll. To funny
MONI
highlandernew highlandernew 13 minutes ago
🔴🔴CITADEL whistleblower FOUND for AMC NAKED algo?:

RICO coming to AMC and NAKED Liquidity Fairies?

*** Click on images to zoom? (if needed?) ***

https://investorshub.advfn.com/uimage/uploads/2024/12/5/uiljdAMC_5X.png

https
AMC
MrLourdes MrLourdes 14 minutes ago
Netlist Inc.’s Recent Legal Victory Against Samsung (case #293): Now Seeking Injunction – Hearing Set for Dec 23, 2024
https://www.linkedin.com/pulse/netlist-incs-recent-legal-victories-against-samsung-landmark-wallach-jnl2e
NLST
ksquared ksquared 14 minutes ago
Howdy, cap. Works for me too.
So good to have America back in charge.
Trump's track record is obviously remembered and
(I believe) welcomed.
America's back. Hail to the Chief.
CALLOUTTHETROLLS CALLOUTTHETROLLS 15 minutes ago
Been gone for a while. Looks like the JOEFUNKYs and REDSPEEDS ARE STILL AT IT. Sad Sad Sad. Watch out for this PUMP AND DUMP. #COVIDISOVER
TOMDF
sharkey1 sharkey1 15 minutes ago
The next gap up will be a dollar, and it could happen tomorrow
ELTP
deepdj011 deepdj011 16 minutes ago
Gets High !!!
DYDXUSD

Your Recent History

Delayed Upgrade Clock